Opinion|Videos|October 3, 2024
Emerging Trends in Chronic GVHD: Promising Clinical Trials and the Future Treatment Landscape
Medical experts discuss emerging trends in chronic GVHD treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Which ongoing clinical trials for cGVHD and prophylaxis are you excited about?
- How do you expect the cGVHD treatment landscape to change in the next couple of years?
- How do you keep informed of updates at major medical congresses?
Advertisement
Related to this article
Weekly oral dordaviprone maintenance after allogeneic transplant produced no DLTs and low rates of grade 3/4 cytopenias in high-risk AML and MDS.
An analysis of 12 randomized trials validated MRD-negative CR as a surrogate for PFS in earlier-line relapsed/refractory multiple myeloma.
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
Lisa Niswander, MD, PhD, of Roswell Park, is investigating ways to combine CAR T cells and a new class of targeted cancer drugs for younger leukemia.
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
UGN-103, a next-generation mitomycin formulation built on the ZUSDURI foundation, is supported by three-month CR and six-month DOR data from the phase 3 UTOPIA trial.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
No efficacy benefit was found in adding SBRT to dual checkpoint blockade, though a subset of patients responded to nivolumab plus ipilimumab.
Advertisement
Advertisement
Trending on OncLive
1
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
2
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
3
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
4
Dr Viansone on ADC Sequencing in Metastatic HER2+ Breast Cancer
5